Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
Zelluna Immunotherapy is developing transformative T cell receptor (TCR) based cellular immunotherapies for the treatment of solid cancers.
Zelluna Immunotherapy was founded in 2016 and is headquartered in Oslo, Oslo, Norway.
Zelluna Immunotherapy is pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable.
Zelluna is combining the broad target range of TCRs with the high potency and allogeneic nature of NK cells to generate innovative cell therapy products that can be supplied in an “off-the-shelf” fashion to treat patients with solid tumours and high unmet medical need.
Zelluna Immunotherapy has raised EUR 7.5M in equity financing and public grants on June 12, 2020.